ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Mucin-1

Mucin-1

概要

Name:Mucin-1
Target Synonym:PEM,Medullary Cystic Kidney Disease 1 (Autosomal Dominant),Tumor Associated Epithelial Mucin,CD227 Antigen,H23 Antigen,MUC-1/SEC,ADMCKD1,Cancer antigen 15-3,Tumor-associated mucin,MUC1-alpha,MUC1-beta,MUC-1/X,MUC1/ZD,Mucin-1,ADMCKD,MCKD1,MAM6,MCKD,MCD,Polymorphic epithelial mucin,PUM,MUC1-NT,Episialin,CD227,MUC1-CT,MUC1,Mucin 1, Cell Surface Associated,Tumor-Associated Epithelial Membrane Antigen,Peanut-Reactive Urinary Mucin,Carcinoma-Associated Mucin,Krebs Von Den Lungen-6,CA 15-3,H23AG,MUC-1,
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:21
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
MU1-M52H4 Mouse Mouse Mucin-1 / MUC-1 (21-535) Protein, His Tag (SPR verified)
MU1-M52H4-structure
MU1-M52H4-sds
MU1-HA2H8 Human APC-Labeled Human Mucin-1 / MUC-1 Protein, His Tag (Site-specific conjugation)
MU1-HA2H8-structure
MU1-H52H7 Human Human Mucin-1 / MUC-1 (24-380) Protein, His Tag (MALS verified)
MU1-H52H7-structure
MU1-H52H7-sds
MU1-H5259 Human Human Mucin-1 / MUC-1 (1098-1158) Protein, Mouse IgG2a Fc Tag
MU1-H5259-structure
MU1-H5259-sds
MU1-H5153 Human Human Mucin-1 / MUC-1 (116-173) Protein, Fc Tag
MU1-H5153-structure
MU1-H5153-sds
MU1-C5252 Cynomolgus Cynomolgus Mucin-1 / MUC-1 Protein, Fc Tag
MU1-C5252-structure
MU1-C5252-sds
MU1-C52H5 Cynomolgus Cynomolgus Mucin-1 / MUC-1 Protein, His Tag
MU1-C52H5-structure
MU1-C52H5-sds
MU1-H5256 Human Human Mucin-1 / MUC-1 (116-173) Protein, Fc Tag
MU1-H5256-structure
MU1-H5256-sds
MU1-H5254 Human Human Mucin-1 / MUC-1 (24-380) Protein, Fc Tag
MU1-H5254-structure
MU1-H5254-sds
MU1-H82E5 Human Biotinylated Human Mucin-1 (890-1158) Protein, His,Avitag™ (MALS verified)
MU1-H82E5-structure
MU1-H82E5-sds
MU1-H52H9 Human Human Mucin-1 / MUC-1 (890-1158) Protein, His Tag (MALS verified)
MU1-H52H9-structure
MU1-H52H9-sds
MU1-H52H5 Human Human Mucin-1 / MUC-1 (1036-1155) Protein, His Tag
MU1-H52H5-structure
MU1-H52H5-sds
MU1-H5255 Human Human Mucin-1 / MUC-1 Protein, Llama IgG2b Fc Tag, low endotoxin
MU1-H5255-structure
MU1-H5255-sds
MU1-H5252 Human Human Mucin-1 / MUC-1 Protein, Fc Tag
MU1-H5252-structure
MU1-H5252-sds
ACRO Quality

生物活性データの一部

MU1-HA2H8-Cell-based assay
Mucin-1 FACS

5e5 of anti-Mucin-1 (F1C) CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Mucin-1 Protein, His Tag (Cat. No. MU1-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

Protocol
MU1-H82E5-Cell-based assay
Mucin-1 FACS

2e5 of Anti-Mucin-1 CAR-293 cells were stained with 100 μL of 0.1 μg/mL of Biotinylated Human Mucin-1, His,Avitag (Cat. No. MU1-H82E5) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

Protocol
MU1-M52H4-SPR
Mucin-1 SPR

Mouse Mucin-1 (21-535) Protein, His Tag (Cat. No. MU1-M52H4) immobilized on CM5 Chip can bind anti-mMUC1-mAb with an affinity constant of 302 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol
MU1-H5254-ELISA
Mucin-1 ELISA

Immobilized Human Mucin-1 (24-380), Fc Tag (Cat. No. MU1-H5254) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Mucin-1 Antibody, Mouse IgG1 (SM-3) with a linear range of 0.5-4 ng/mL (QC tested).

Protocol

Synonym Name

Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1,SEC,MUC-1,X,MUC1,ZD,PEM,PEMT,PUM,CA15-3,Episialin

Background

Membrane mucins have several functions in epithelial cells including cytoprotection, extravasation during metastases, maintenance of luminal structure, and signal transduction. MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites. Interacts via its C-terminus with PDZK1 and this interaction appears important for proper localization. Probably plays a role in maintaining homeostasis on mucosal surfaces.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) CVAC-301; CV-301 Phase 2 Clinical Therion Biologics Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma Details
Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) Phase 2 Clinical Guangzhou Anjie Biomedical Technology Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Anti-MUC1 monoclonal antibody (OncoQuest) AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 Phase 2 Clinical Altarex Pancreatic Neoplasms Details
Adenoviral MUC1 vaccine (Etubics) ETBX-061; Ad5-MUC1 Phase 2 Clinical Etubics Corp, Immunitybio Inc, Nantkwest Inc Chordoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell Details
GO-2032c GO-203-2C Phase 2 Clinical Genus Oncology Llc, Dana-Farber Cancer Institute Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute Details
MUC1-Poly-ICLC MUC1-poly-ICLC Phase 2 Clinical University Of Pittsburgh Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BLP25 liposome vaccine BLP-25; L-BLP25; ONO-7165; LP-BLP-25; EMD-531444 Phase 2 Clinical Cascadian Therapeutics Inc Rectal Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
DS-3939 DS-3939; DS-3939a Phase 2 Clinical Daiichi Sankyo Inc Solid tumours; Neoplasm Metastasis Details
BromAc Phase 2 Clinical Mucpharm Pty Ltd Coronavirus Disease 2019 (COVID-19); Pneumonia, Ventilator-Associated Details
BM7PE Phase 2 Clinical Oslo University Hospital Colorectal Neoplasms Details
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) Phase 2 Clinical The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney Carcinoma, Non-Small-Cell Lung Details
huMNC2-CAR44 huMNC2-CAR44 Phase 1 Clinical Minerva Biotechnologies Breast Neoplasms Details
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms Details
Gatipotuzumab GT-MAB-2.5-GEX Phase 1 Clinical Nemod, Glycotope Gmbh Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
P-MUC1C-ALLO1 P-MUC1C-ALLO1; P-MUC1C-101 Phase 1 Clinical Poseida Therapeutics Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MUC1-peptide-DC-CTL (Beijing Doing Biomedical) Phase 1 Clinical Beijing Doing Biomedical Co Ltd Stomach Neoplasms Details
MUC1-gene-DC-CTL (Beijing Doing Biomedical) Phase 1 Clinical Beijing Doing Biomedical Co Ltd Stomach Neoplasms Details
Recombinant HSP-MUC1 fusion protein (Newsummit) Phase 1 Clinical Shanghai Xinshengyuan Biological Medicine Co Ltd Breast Neoplasms Details
DXC-005 DXC-005 Phase 1 Clinical Hangzhou Dac Biotech Company Ltd Solid tumours Details
M-1231 M-1231 Phase 1 Clinical Emd Serono Research & Development Institute Inc, Merck Serono Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
ICTCAR-046 ICTCAR-046 Clinical Innovative Cellular Therapeutics Co Ltd Pancreatic Neoplasms Details
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) CVAC-301; CV-301 Phase 2 Clinical Therion Biologics Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma Details
Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) Phase 2 Clinical Guangzhou Anjie Biomedical Technology Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Anti-MUC1 monoclonal antibody (OncoQuest) AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 Phase 2 Clinical Altarex Pancreatic Neoplasms Details
Adenoviral MUC1 vaccine (Etubics) ETBX-061; Ad5-MUC1 Phase 2 Clinical Etubics Corp, Immunitybio Inc, Nantkwest Inc Chordoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell Details
GO-2032c GO-203-2C Phase 2 Clinical Genus Oncology Llc, Dana-Farber Cancer Institute Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute Details
MUC1-Poly-ICLC MUC1-poly-ICLC Phase 2 Clinical University Of Pittsburgh Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BLP25 liposome vaccine BLP-25; L-BLP25; ONO-7165; LP-BLP-25; EMD-531444 Phase 2 Clinical Cascadian Therapeutics Inc Rectal Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
DS-3939 DS-3939; DS-3939a Phase 2 Clinical Daiichi Sankyo Inc Solid tumours; Neoplasm Metastasis Details
BromAc Phase 2 Clinical Mucpharm Pty Ltd Coronavirus Disease 2019 (COVID-19); Pneumonia, Ventilator-Associated Details
BM7PE Phase 2 Clinical Oslo University Hospital Colorectal Neoplasms Details
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) Phase 2 Clinical The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney Carcinoma, Non-Small-Cell Lung Details
huMNC2-CAR44 huMNC2-CAR44 Phase 1 Clinical Minerva Biotechnologies Breast Neoplasms Details
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms Details
Gatipotuzumab GT-MAB-2.5-GEX Phase 1 Clinical Nemod, Glycotope Gmbh Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
P-MUC1C-ALLO1 P-MUC1C-ALLO1; P-MUC1C-101 Phase 1 Clinical Poseida Therapeutics Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MUC1-peptide-DC-CTL (Beijing Doing Biomedical) Phase 1 Clinical Beijing Doing Biomedical Co Ltd Stomach Neoplasms Details
MUC1-gene-DC-CTL (Beijing Doing Biomedical) Phase 1 Clinical Beijing Doing Biomedical Co Ltd Stomach Neoplasms Details
Recombinant HSP-MUC1 fusion protein (Newsummit) Phase 1 Clinical Shanghai Xinshengyuan Biological Medicine Co Ltd Breast Neoplasms Details
DXC-005 DXC-005 Phase 1 Clinical Hangzhou Dac Biotech Company Ltd Solid tumours Details
M-1231 M-1231 Phase 1 Clinical Emd Serono Research & Development Institute Inc, Merck Serono Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
ICTCAR-046 ICTCAR-046 Clinical Innovative Cellular Therapeutics Co Ltd Pancreatic Neoplasms Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap